Severe Anemia

2

Review clinical trials related to Severe Anemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Anemia Therapy in Patients With Infective Endocarditis

Infective endocarditis (IE) is a bacterial infection of the heart valves, inserted material or surrounding struc-tures and is associated with a high morbidity and mortality. In patients with IE, anemia is considered to result from the underlying infection, prolonged sustained inflammatory response due to the often slow natural course of the disease, and coexisting comorbidities. Previous studies have found that moderate to severe anemia is associated with a markedly higher risk of mortality in the 6-months recovery phase following treatment for IE. In many cardiac patients and patients with chronic inflammation, randomized trials have shown benefit of treatment of anemia with adjunctive therapy i.e., vitamins (vitamin B12/folic acid), intravenous iron, and erythropoiesis stimulating agents in alleviating anemia, without increased risk of infection. Despite these findings, anemia screening and management are not addressed in current endocarditis guidelines. Thus, in patients with IE and anemia, adjunctive treatment of the anemia might be beneficial for recovery and improve outcomes. The aim of POET-IRON is to assess the efficacy of adjunctive anemia treatment in patients with IE, using intravenous iron supplementation, erythropoietin-stimulated erythropoiesis, and dietary optimization including vitamins if necessary, and its effect on hemoglobin levels compared to standard care. The investigators hypothesize that this intervention is safe and will increase hemoglobin concentration, thereby alleviating symptoms of anemia and improving clinical outcomes through enhanced oxygen-carrying capacity, tissue oxygenation, and functional status.

Participants needed: 74
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Rigshospitalet, DenmarkUpdated: May 29, 2026Locations: 1
Eligibility criteria

18 years or older [+8]

Known or suspected immunocompromise (e.g., HIV infection, ongoing chemotherapy,... [+7]

Status: Recruiting

PDMC Implementation Trial in Kenya

The goal of this implementation trial is to evaluate at least two alternative delivery strategies and adherence support for malaria chemoprevention with dihydroartemisinin-piperaquine in the post-discharge management of children hospitalised with severe anaemia or severe malaria to optimise adherence in Kenya. The actual interventions to be evaluated have been co-designed with national stakeholders during an initial formative research stage.

Participants needed: 600
Trial details
Phase: Phase 4Age: Up to 9Biological sex: AllType: InterventionalSponsor: Liverpool School of Tropical MedicineUpdated: Nov 21, 2025Locations: 1
Eligibility criteria

Health facilities with blood transfusion services offering in-patient care for c... [+5]

Recognised specific other causes of severe anaemia (i.e., trauma, haematological... [+3]